Table of Contents Author Guidelines Submit a Manuscript
Advances in Medicine
Volume 2014, Article ID 317980, 18 pages
http://dx.doi.org/10.1155/2014/317980
Review Article

Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment

Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Medical Faculty Mannheim, Heidelberg University, P.O. Box 12 21 20, 68072 Mannheim, Germany

Received 19 January 2014; Accepted 19 May 2014; Published 11 June 2014

Academic Editor: Stephen J. Glatt

Copyright © 2014 Mathias Zink. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. R. Insel and E. M. Scolnick, “Cure therapeutics and strategic prevention: raising the bar for mental health research,” Molecular Psychiatry, vol. 11, no. 1, pp. 11–17, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Hasan, P. Falkai, T. Wobrock et al., “World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects,” The World Journal of Biological Psychiatry, vol. 14, no. 1, pp. 2–44, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Gaebel, M. Riesbeck, and T. Wobrock, “Schizophrenia guidelines across the world: a selective review and comparison,” International Review of Psychiatry, vol. 23, no. 4, pp. 379–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. M. Grant, G. A. Huh, D. Perivoliotis, N. M. Stolar, and A. T. Beck, “Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia,” Archives of General Psychiatry, vol. 69, no. 2, pp. 121–127, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. F. Lehman, J. A. Lieberman, L. B. Dixon et al., “Practice guideline for the treatment of partients with schizophrenia, second edition,” American Journal of Psychiatry, vol. 161, no. 2, p. 56, 2004. View at Google Scholar · View at Scopus
  6. F. Sarin, L. Wallin, and B. Widerlöv, “Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials,” Nordic Journal of Psychiatry, vol. 65, no. 3, pp. 162–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Schirmbeck and M. Zink, “Cognitive-behavioural therapy for obsessive-compulsive symptoms in schizophrenia,” The Cognitive Behavioural therapist, vol. 6, Article ID 175447, 13 pages, 2013. View at Publisher · View at Google Scholar
  8. T. Wykes, C. Steel, B. Everitt, and N. Tarrier, “Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor,” Schizophrenia Bulletin, vol. 34, no. 3, pp. 523–537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. C. Angermeyer, H. Matschinger, and G. Schomerus, “Attitudes towards psychiatric treatment and people with mental illness: changes over two decades,” British Journal of Psychiatry, vol. 203, no. 2, pp. 146–151, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Leucht, S. Hierl, W. Kissling, M. Dold, and J. M. Davis, “Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses,” British Journal of Psychiatry, vol. 200, no. 2, pp. 97–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. van Os and S. Kapur, “Schizophrenia,” The Lancet, vol. 374, no. 9690, pp. 635–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Jakob and H. Beckmann, “Prenatal developmental disturbances in the limbic allocortex in schizophrenics,” Journal of Neural Transmission, vol. 65, no. 3-4, pp. 303–326, 1986. View at Google Scholar · View at Scopus
  13. H. Jakob and H. Beckmann, “Gross and histological criteria for developmental disorders in brains of schizophrenics,” Journal of the Royal Society of Medicine, vol. 82, no. 8, pp. 466–469, 1989. View at Google Scholar · View at Scopus
  14. T. J. Raedler, M. B. Knable, and D. R. Weinberger, “Schizophrenia as a developmental disorder of the cerebral cortex,” Current Opinion in Neurobiology, vol. 8, no. 1, pp. 157–161, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. O. D. Howes, J. Kambeitz, E. Kim et al., “The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysisof imaging studies,” Archives of General Psychiatry, vol. 69, no. 8, pp. 776–786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. D. Stan and D. A. Lewis, “Altered cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies,” Current Pharmaceutical Biotechnology, vol. 13, no. 8, pp. 1557–1562, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Zink, Plasticity of Brain Development As A Perspective of Basic Science in Psychiatry, Shaker, 2007.
  18. T. L. Bale, T. Z. Baram, A. S. Brown et al., “Early life programming and neurodevelopmental disorders,” Biological Psychiatry, vol. 68, no. 4, pp. 314–319, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Schmitt and P. Falkai, “Therapeutic targets in major psychiatric disorders revisited,” European Archives of Psychiatry and Clinical Neuroscience, vol. 263, no. 8, pp. 619–620, 2013. View at Publisher · View at Google Scholar
  20. T. R. Insel, “Rethinking schizophrenia,” Nature, vol. 468, no. 7321, pp. 187–193, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Graybiel and S. L. Rauch, “Toward a neurobiology of obsessive-compulsive disorder,” Neuron, vol. 28, no. 2, pp. 343–347, 2000. View at Google Scholar · View at Scopus
  22. S. Karch and O. Pogarell, “Neurobiologie der zwangsstörung,” Der Nervenarzt, vol. 82, no. 3, pp. 299–307, 2011. View at Publisher · View at Google Scholar
  23. O. Pogarell, C. Hamann, G. Pöpperl et al., “Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder,” Biological Psychiatry, vol. 54, no. 12, pp. 1406–1413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Saxena, A. L. Brody, J. M. Schwartz, and L. R. Baxter, “Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder,” British Journal of Psychiatry, vol. 173, no. 35, pp. 26–37, 1998. View at Google Scholar · View at Scopus
  25. B. Bandelow, J. Zohar, E. Hollander et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision,” World Journal of Biological Psychiatry, vol. 9, no. 4, pp. 248–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Nakao, A. Nakagawa, T. Yoshiura et al., “Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study,” Biological Psychiatry, vol. 57, no. 8, pp. 901–910, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Saxena, A. L. Brody, K. M. Maidment et al., “Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder,” Neuropsychopharmacology, vol. 21, no. 6, pp. 683–693, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. D. E. J. Linden, “How psychotherapy changes the brain—the contribution of functional neuroimaging,” Molecular Psychiatry, vol. 11, no. 6, pp. 528–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Saxena, E. Gorbis, J. O'Neill et al., “Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder,” Molecular Psychiatry, vol. 14, no. 2, pp. 197–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Veenstra-VanderWeele, S.-J. Kim, D. Gonen, G. L. Hanna, B. L. Leventhal, and E. H. Cook Jr., “Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessive-compulsive disorder,” Molecular Psychiatry, vol. 6, no. 2, pp. 160–167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Albelda, N. Bar-On, and D. Joel, “The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder,” Psychopharmacology, vol. 210, no. 1, pp. 13–24, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Joel, “Current animal models of obsessive compulsive disorder: a critical review,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 3, pp. 374–388, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Porton, B. D. Greenberg, K. Askland et al., “Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder,” Translational Psychiatry, vol. 3, article e259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. X. W. Yang and X.-H. Lu, “Molecular and cellular basis of obsessive-compulsive disorder-like behaviors: emerging view from mouse models,” Current Opinion in Neurology, vol. 24, no. 2, pp. 114–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Starck, M. Ljungberg, M. Nilsson et al., “A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity,” Journal of Neural Transmission, vol. 115, no. 7, pp. 1051–1062, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. S. P. Whiteside, J. D. Port, B. J. Deacon, and J. S. Abramowitz, “A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety,” Psychiatry Research, vol. 146, no. 2, pp. 137–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. V. Coric, S. Taskiran, C. Pittenger et al., “Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial,” Biological Psychiatry, vol. 58, no. 5, pp. 424–428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Grados, M. W. Specht, H. M. Sung, and D. Fortune, “Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach,” Expert Opinion on Drug Discovery, pp. 1–13, 2013. View at Publisher · View at Google Scholar
  39. D. L. Lafleur, C. Pittenger, B. Kelmendi et al., “N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder,” Psychopharmacology, vol. 184, no. 2, pp. 254–256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Pittenger, J. H. Krystal, and V. Coric, “Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder,” NeuroRx, vol. 3, no. 1, pp. 69–81, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Poyurovsky, I. Glick, and L. M. Koran, “Lamotrigine augmentation in schizophrenia and schizoaffective patients with obsessive-compulsive symptoms,” Journal of Psychopharmacology, vol. 24, no. 6, pp. 861–866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Poyurovsky, R. Weizman, A. Weizman, and L. Koran, “Memantine for treatment-resistant OCD,” American Journal of Psychiatry, vol. 162, no. 11, pp. 2191–2192, 2005. View at Google Scholar · View at Scopus
  43. O. J. Bienvenu, Y. Wang, Y. Y. Shugart et al., “Sapap3 and pathological grooming in humans: results from the OCD collaborative genetics study,” American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 150, no. 5, pp. 710–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Nicolini, P. Arnold, G. Nestadt, N. Lanzagorta, and J. L. Kennedy, “Overview of genetics and obsessive-compulsive disorder,” Psychiatry Research, vol. 170, no. 1, pp. 7–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. L. Pauls, “The genetics of obsessive-compulsive disorder: a review,” Dialogues in Clinical Neuroscience, vol. 12, no. 2, pp. 149–163, 2010. View at Google Scholar · View at Scopus
  46. S. Hargreaves, “NICE guidelines address social aspect of schizophrenia,” BMJ, vol. 326, no. 7391, p. 679, 2003. View at Google Scholar · View at Scopus
  47. M. Zink, S. Englisch, and A. Meyer-Lindenberg, “Polypharmacy in schizophrenia,” Current Opinion in Psychiatry, vol. 23, no. 2, pp. 103–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. I. Gava, C. Barbui, E. Aguglia et al., “Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD),” Cochrane Database of Systematic Reviews, vol. 18, no. 2, 2007. View at Google Scholar · View at Scopus
  49. L. M. Koran, G. L. Hanna, E. Hollander, G. Nestadt, and H. B. Simpson, “Practice guideline for the treatment of patients with obsessive-compulsive disorder work group on obsessive-compulsive disorder,” American Journal of Psychiatry, vol. 164, no. 7, pp. 1–53, 2007. View at Google Scholar · View at Scopus
  50. A. K. Kuelz and U. Voderholzer, “Psychotherapie der Zwangsstörung,” Der Nervenarzt, vol. 82, no. 3, pp. 308–318, 2011. View at Publisher · View at Google Scholar
  51. A. I. Rosa-Alcázar, J. Sánchez-Meca, A. Gómez-Conesa, and F. Marín-Martínez, “Psychological treatment of obsessive-compulsive disorder: a meta-analysis,” Clinical Psychology Review, vol. 28, no. 8, pp. 1310–1325, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. H. Bloch, A. Landeros-Weisenberger, B. Kelmendi, V. Coric, M. B. Bracken, and J. F. Leckman, “A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder,” Molecular Psychiatry, vol. 11, no. 7, pp. 622–632, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Dold, M. Aigner, R. Lanzenberger, and S. Kasper, “Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder a meta-analysis of double-blind, randomised, placebo-controlled trials,” Fortschritte der Neurologie Psychiatrie, vol. 79, no. 8, pp. 453–466, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. N. A. Fineberg, T. M. Gale, and T. Sivakumaran, “A review of antipsychotics in the treatment of obsessive compulsive disorder,” Journal of Psychopharmacology, vol. 20, no. 1, pp. 97–103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. A. M. Achim, M. Maziade, É. Raymond, D. Olivier, C. Mérette, and M.-A. Roy, “How prevalent are anxiety disorders in schizophrenia? a meta-analysis and critical review on a significant association,” Schizophrenia Bulletin, vol. 37, no. 4, pp. 811–821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Bosanac, S. Mancuso, and D. Castle, “Anxiety symptoms in psychotic disorders,” Clinical Schizophrenia & Related Psychoses, vol. 18, pp. 1–22, 2013. View at Google Scholar
  57. P. F. Buckley, B. J. Miller, D. S. Lehrer, and D. J. Castle, “Psychiatric comorbidities and schizophrenia,” Schizophrenia Bulletin, vol. 35, no. 2, pp. 383–402, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Hadi, Y. Greenberg, and P. Sirota, “Obsessivecompulsive symptoms in schizophrenia: prevalence, clinical features and treatment. A literature review,” The World Journal of Biological Psychiatry, vol. 13, no. 1, pp. 2–13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. P. H. Lysaker and K. A. Whitney, “Obsessive-compulsive symptoms in schizophrenia: prevalence, correlates and treatment,” Expert Review of Neurotherapeutics, vol. 9, no. 1, pp. 99–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Mukhopadhaya, R. Krishnaiah, T. Taye et al., “Obsessive-compulsive disorder in UK clozapine-treated schizophrenia and schizoaffective disorder: a cause for clinical concern,” Journal of Psychopharmacology, vol. 23, no. 1, pp. 6–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Poyurovsky, A. Weizman, and R. Weizman, “Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment,” CNS Drugs, vol. 18, no. 14, pp. 989–1010, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Poyurovsky, J. Zohar, I. Glick et al., “Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications,” Comprehensive Psychiatry, vol. 53, no. 5, pp. 480–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Swets, J. Dekker, K. van Emmerik-van Oortmerssen et al., “The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates,” Schizophrenia Research, vol. 152, no. 2-3, pp. 458–468, 2014. View at Google Scholar
  64. D. L. Murphy, K. R. Timpano, M. G. Wheaton, B. D. Greenberg, and E. C. Miguel, “Obsessive-compulsive disorder and its related disorders: a reappraisal of obsessive-compulsive spectrum concepts,” Dialogues in Clinical Neuroscience, vol. 12, no. 2, pp. 131–148, 2010. View at Google Scholar · View at Scopus
  65. L. De Haan, C. Dudek-Hodge, Y. Verhoeven, and D. Denys, “Prevalence of psychotic disorders in patients with obsessive-compulsive disorder,” CNS Spectrums, vol. 14, no. 8, pp. 415–417, 2009. View at Google Scholar · View at Scopus
  66. R. Cunill, X. Castells, and D. Simeon, “Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis,” Journal of Clinical Psychiatry, vol. 70, no. 1, pp. 70–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. A. R. Sa, A. G. Hounie, A. S. Sampaio, J. Arrais, E. C. Miguel, and H. Elkis, “Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol,” Comprehensive Psychiatry, vol. 50, no. 5, pp. 437–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Schirmbeck, F. Rausch, S. Englisch et al., “Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study,” Schizophrenia Bulletin, vol. 39, no. 6, pp. 1261–1271, 2013. View at Publisher · View at Google Scholar
  69. I. Berman, A. Kalinowski, S. M. Berman, J. Lengua, and A. I. Green, “Obsessive and compulsive symptoms in chronic schizophrenia,” Comprehensive Psychiatry, vol. 36, no. 1, pp. 6–10, 1995. View at Google Scholar · View at Scopus
  70. L. De Haan, B. Sterk, L. Wouters, and D. H. Linszen, “The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders,” Schizophrenia Bulletin, vol. 39, no. 1, pp. 151–160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. W. S. Fenton and T. H. McGlashan, “The prognostic significance of obsessive-compulsive symptoms in schizophrenia,” American Journal of Psychiatry, vol. 143, no. 4, pp. 437–441, 1986. View at Google Scholar · View at Scopus
  72. P. H. Lysaker, R. S. Lancaster, M. A. Nees, and L. W. Davis, “Patterns of obsessive-compulsive symptoms and social function in schizophrenia,” Psychiatry Research, vol. 125, no. 2, pp. 139–146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Öngür and D. C. Goff, “Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status,” Schizophrenia Research, vol. 75, no. 2-3, pp. 349–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Schirmbeck and M. Zink, “Obsessive-compulsive syndromes in schizophrenia: a case for polypharmacy?” in Polypharmacy In Psychiatric Practice, M. Ritsner, Ed., ISBN 978-94-007-5798-1, Springer, 2013. View at Google Scholar
  75. M. Fink and M. A. Taylor, “The many varieties of catatonia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 251, no. 1, pp. 8–13, 2001. View at Google Scholar · View at Scopus
  76. M. Doyle, A. N. Chorcorain, E. Griffith, T. Trimble, and E. O'Callaghan, “Obsessive compulsive symptoms in patients with Schizophrenia on Clozapine and with Obsessive Compulsive disorder: a comparison study,” Comprehensive Psychiatry, vol. 55, no. 1, pp. 130–136, 2014. View at Publisher · View at Google Scholar
  77. P. Oulis, G. Konstantakopoulos, L. Lykouras, and P. G. Michalapoulou, “Differential diagnosis of obsessive-compulsive symptoms from delusions in schizophrenia: a phenomenological approach,” World Journal of Psychiatry, vol. 3, pp. 50–56, 2013. View at Google Scholar
  78. M. Fink, “Rediscovering catatonia: the biography of a treatable syndrome,” Acta Psychiatrica Scandinavica, vol. 127, no. 441, pp. 1–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Bräunig, S. Krüger, G. Shugar, J. Höffler, and I. Börner, “The catatonia rating scale I—development, reliability, and use,” Comprehensive Psychiatry, vol. 41, no. 2, pp. 147–158, 2000. View at Publisher · View at Google Scholar
  80. L. de Haan, B. Hoogeboom, N. Beuk, L. Wouters, P. M. A. J. Dingemans, and D. H. Linszen, “Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients,” Psychopharmacology bulletin, vol. 39, no. 1, pp. 25–30, 2006. View at Google Scholar · View at Scopus
  81. S. R. Woody, G. Steketee, and D. L. Chambless, “Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale,” Behaviour Research and Therapy, vol. 33, no. 5, pp. 597–605, 1995. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Beckmann, A. J. Bartsch, K.-J. Neumarker, B. Pfuhlmann, M. F. Verdaguer, and E. Franzek, “Schizophrenias in the Wernicke-Kleist-Leonhard school,” American Journal of Psychiatry, vol. 157, no. 6, pp. 1024–1025, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Zink, F. Schirmbeck, F. Rausch et al., “Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function,” Acta Psychiatrica Scandinavica. View at Publisher · View at Google Scholar
  84. A. Bechdolf, H. Müller, H. Stützer et al., “Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (Prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis,” Schizophrenia Bulletin, vol. 37, no. 2, pp. S111–S121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. J.-W. Hur, N. Y. Shin, J. H. Jang et al., “Clinical and neurocognitive profiles of subjects at high risk for psychosis with and without obsessive-compulsive symptoms,” Australian and New Zealand Journal of Psychiatry, vol. 46, no. 2, pp. 161–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. T. A. Niendam, J. Berzak, T. D. Cannon, and C. E. Bearden, “Obsessive compulsive symptoms in the psychosis prodrome: correlates of clinical and functional outcome,” Schizophrenia Research, vol. 108, no. 1-3, pp. 170–175, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Shioiri, K. Shinada, H. Kuwabara, and T. Someya, “Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia,” Psychiatry and Clinical Neurosciences, vol. 61, no. 4, pp. 348–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. B. Sterk, K. Lankreijer, D. H. Linszen, and L. De Haan, “Obsessivecompulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms,” Australian and New Zealand Journal of Psychiatry, vol. 45, no. 5, pp. 400–406, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. J. E. DeVylder, A. J. Oh, S. Ben-David, N. Azimov, J. M. Harkavy-Friedman, and C. M. Corcoran, “Obsessive compulsive symptoms in individuals at clinical risk for psychosis: association with depressive symptoms and suicidal ideation,” Schizophrenia Research, vol. 140, no. 1–3, pp. 110–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. L. F. Fontenelle, A. Lin, C. Pantelis, S. J. Wood, B. Nelson, and A. R. Yung, “A longitudinal study of obsessive-compulsive disorder in individuals at ultra-high risk for psychosis,” Journal of Psychiatric Research, vol. 45, no. 9, pp. 1140–1145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Fusar-Poli, B. Nelson, L. Valmaggia, A. R. Yung, and P. K. McGuire, “Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis,” Schizophrenia Bulletin, vol. 40, no. 1, pp. 120–131, 2014. View at Publisher · View at Google Scholar
  92. I. A. Rubino, E. Frank, R. Croce Nanni, D. Pozzi, T. Lanza Di Scalea, and A. Siracusano, “A comparative study of axis I antecedents before age 18 of unipolar depression, bipolar disorder and schizophrenia,” Psychopathology, vol. 42, no. 5, pp. 325–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. L. De Haan, A. Oekeneva, T. Van Amelsvoort, and D. Linszen, “Obsessive-compulsive disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders,” European Psychiatry, vol. 19, no. 8, p. 524, 2004. View at Publisher · View at Google Scholar · View at Scopus
  94. L. de Haan, B. Sterk, and R. van der Valk, “Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life,” Early Intervention in Psychiatry, vol. 7, no. 3, pp. 285–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Poyurovsky, C. Fuchs, and A. Weizman, “Obsessive-compulsive disorder in patients with first-episode schizophrenia,” American Journal of Psychiatry, vol. 156, no. 12, pp. 1998–2000, 1999. View at Google Scholar · View at Scopus
  96. L. F. Fontenelle, A. Lin, C. Pantelis, S. J. Wood, B. Nelson, and A. R. Yung, “Markers of vulnerability to obsessive-compulsive disorder in an ultra-high risk sample of patients who developed psychosis,” Early Intervention in Psychiatry, vol. 6, no. 2, pp. 201–206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Van Dael, J. Van Os, R. De Graaf, M. Ten Have, L. Krabbendam, and I. Myin-Germeys, “Can obsessions drive you mad? Longitudinal evidence that obsessive-compulsive symptoms worsen the outcome of early psychotic experiences,” Acta Psychiatrica Scandinavica, vol. 123, no. 2, pp. 136–146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Y. Hwang, S.-W. Kim, S. Y. Yum, and L. A. Opler, “Management of schizophrenia with obsessive-compulsive features,” Psychiatric Clinics of North America, vol. 32, no. 4, pp. 835–851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. F. Schirmbeck, F. Rausch, S. Englisch et al., “Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study,” Journal of Psychopharmacology, vol. 27, no. 4, pp. 349–357, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Oberbeck, K. Stengler, and H. Steinberg, “Die geschichte der zwangserkrankung: ihre stellung im wandel der psychiatrischen formenlehre bis anfang des 20. jahrhunderts,” Fortschritte der Neurologie-Psychiatrie, vol. 81, no. 12, pp. 706–714, 2013. View at Publisher · View at Google Scholar
  101. F. G. Dowling, M. T. Pato, and C. N. Pato, “Comorbidity of obsessive-compulsive and psychotic symptoms: a review,” Harvard Review of Psychiatry, vol. 3, no. 2, pp. 75–83, 1995. View at Google Scholar · View at Scopus
  102. E. Stengel, “A study on some clinical aspects of the relationship between obsessional neurosis and psychotic reaction types,” Journal of Mental Science, vol. 91, pp. 166–187, 1945. View at Publisher · View at Google Scholar
  103. F. Guillem, J. Satterthwaite, T. Pampoulova, and E. Stip, “Relationship between psychotic and obsessive compulsive symptoms in schizophrenia,” Schizophrenia Research, vol. 115, no. 2-3, pp. 358–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Poyurovsky, S. Faragian, A. Pashinian et al., “Clinical characteristics of schizotypal-related obsessive-compulsive disorder,” Psychiatry Research, vol. 159, no. 1-2, pp. 254–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Poyurovsky and L. M. Koran, “Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications,” Journal of Psychiatric Research, vol. 39, no. 4, pp. 399–408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. F. Catapano, F. Perris, M. Fabrazzo et al., “Obsessive-compulsive disorder with poor insight: a three-year prospective study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 2, pp. 323–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Tumkaya, F. Karadag, N. K. Oguzhanoglu et al., “Schizophrenia with obsessive-compulsive disorder and obsessive-compulsive disorder with poor insight: a neuropsychological comparison,” Psychiatry Research, vol. 165, no. 1-2, pp. 38–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Poyurovsky, Schizo-Obsessive Disorder, Cambridge University Press, Cambridge, Mass, USA, 2013.
  109. M. Y. Hwang, J. E. Morgan, and M. F. Losconzcy, “Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 12, no. 1, pp. 91–94, 2000. View at Google Scholar · View at Scopus
  110. A. Bottas, R. G. Cooke, and M. A. Richter, “Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?” Journal of Psychiatry and Neuroscience, vol. 30, no. 3, pp. 187–193, 2005. View at Google Scholar · View at Scopus
  111. I. Reznik, M. Kotler, A. Weizman, and P. H. Lysaker, “Obsessive and compulsive symptoms in schizophrenia patients—from neuropsychology to clinical typology and classification,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 17, no. 2, pp. 254–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. I. Reznik, R. Mester, M. Kotler et al., “Obsessive-compulsive schizophrenia: a new diagnostic entity?” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 13, no. 1, pp. 115–116, 2001. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Poyurovsky, S. Faragiae, A. Pashinian et al., “Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 19, no. 2, pp. 145–150, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. L. Sevincok, A. Akoglu, and H. Arslantas, “Schizo-obsessive and obsessive-compulsive disorder: comparison of clinical characteristics and neurological soft signs,” Psychiatry Research, vol. 145, no. 2-3, pp. 241–248, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. P. H. Lysaker, K. A. Whitney, and L. W. Davis, “Associations of executive function with concurrent and prospective reports of obsessive-compulsive symptoms in schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 21, no. 1, pp. 38–42, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. P. H. Lysaker, G. J. Bryson, K. A. Marks, T. C. Greig, and M. D. Bell, “Association of obsessions and compulsions in schizophrenia with neurocognition and negative symptoms,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 14, no. 4, pp. 449–453, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Gross-Isseroff, H. Hermesh, J. Zohar, and A. Weizman, “Neuroimaging communality between schizophrenia and obsessive compulsive disorder: a putative basis for schizo-obsessive disorder?” World Journal of Biological Psychiatry, vol. 4, no. 3, pp. 129–134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. H. Ebel, G. Gross, J. Klosterkotter, and G. Huber, “Basic symptoms in schizophrenic and affective psychoses,” Psychopathology, vol. 22, no. 4, pp. 224–232, 1989. View at Google Scholar · View at Scopus
  119. L. Süllwold and G. Huber, “Basic schizophrenic disorders,” Monographien aus dem Gesamtgebiete der Psychiatrie, vol. 42, pp. 1–177, 1986. View at Google Scholar · View at Scopus
  120. F. Schirmbeck, D. Mier, C. Esslinger et al., “Increased orbitofrontal cortex activation during treatment with pro-obsessive antipsychotic drugs,” submitted to Neuropsychopharmacology.
  121. A. K. Kuelz, F. Hohagen, and U. Voderholzer, “Neuropsychological performance in obsessive-compulsive disorder: a critical review,” Biological Psychology, vol. 65, no. 3, pp. 185–236, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Hermesh, A. Weizman, S. Gur et al., “Alternation learning in OCD/schizophrenia patients,” European Neuropsychopharmacology, vol. 13, no. 2, pp. 87–91, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. J. H. Meijer, M. Swets, S. Keeman, D. H. Nieman, C. J. Meijer, and L. De Haan, “Is a schizo-obsessive subtype associated with cognitive impairment?: results from a large cross-sectional study in patients with psychosis and their unaffected relatives,” Journal of Nervous and Mental Disease, vol. 201, no. 1, pp. 30–35, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. P. G. Michalopoulou, G. Konstantakopoulos, M. Typaldou et al., “Can cognitive deficits differentiate between schizophrenia with and without obsessive-compulsive symptoms?” Comprehensive Psychiatry, vol. 55, no. 4, pp. 1015–1021, 2014. View at Publisher · View at Google Scholar
  125. A. Tiryaki and E. Özkorumak, “Do the obsessive-compulsive symptoms have an effect in schizophrenia?” Comprehensive Psychiatry, vol. 51, no. 4, pp. 357–362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. K. A. Whitney, P. S. Fastenau, J. D. Evans, and P. H. Lysaker, “Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms,” Schizophrenia Research, vol. 69, no. 1, pp. 75–83, 2004. View at Publisher · View at Google Scholar · View at Scopus
  127. A. Borkowska, E. Pilaczyñska, and J. K. Rybakowski, “The frontal lobe neuropsychological tests in patients with schizophrenia and/or obsessive-compulsive disorder,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 15, no. 3, pp. 359–362, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. M.-J. Lee, Y.-B. Shin, Y.-K. Sunwoo et al., “Comparative analysis of cognitive function in schizophrenia with and without obsessive compulsive disorder,” Psychiatry Investigation, vol. 6, no. 4, pp. 286–293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. R. Cunill, E. Huerta-Ramos, and X. Castells, “The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis,” Psychiatry Research, vol. 210, no. 1, pp. 21–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. S. R. Kumbhani, R. M. Roth, C. L. Kruck, L. A. Flashman, and T. W. McAllister, “Nonclinical obsessive-compulsive symptoms and executive functions in schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 3, pp. 304–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  131. D. D. Patel, K. R. Laws, A. Padhi et al., “The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis,” Psychological Medicine, vol. 40, no. 6, pp. 921–933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  132. I. Berman, A. Merson, B. Viegner, M. F. Losonczy, D. Pappas, and A. I. Green, “Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study,” Journal of Nervous and Mental Disease, vol. 186, no. 3, pp. 150–156, 1998. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Schirmbeck, C. Esslinger, F. Rausch, S. Englisch, A. Meyer-Lindenberg, and M. Zink, “Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia,” Psychological Medicine, vol. 41, no. 11, pp. 2361–2373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  134. G. Rajender, M. S. Bhatia, K. Kanwal, S. Malhotra, T. B. Singh, and D. Chaudhary, “Study of neurocognitive endophenotypes in drug-naïve obsessive-compulsive disorder patients, their first-degree relatives and healthy controls,” Acta Psychiatrica Scandinavica, vol. 124, no. 2, pp. 152–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. L. Friedlander and M. Desrocher, “Neuroimaging studies of obsessive-compulsive disorder in adults and children,” Clinical Psychology Review, vol. 26, no. 1, pp. 32–49, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. S. P. Whiteside, J. D. Port, and J. S. Abramowitz, “A meta-analysis of functional neuroimaging in obsessive-compulsive disorder,” Psychiatry Research, vol. 132, no. 1, pp. 69–79, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. A. Del Casale, G. D. Kotzalidis, C. Rapinesi et al., “Functional neuroimaging in obsessive-compulsive disorder,” Neuropsychobiology, vol. 64, no. 2, pp. 61–85, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Meyer-Lindenberg, “From maps to mechanisms through neuroimaging of schizophrenia,” Nature, vol. 468, no. 7321, pp. 194–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  139. F. Aoyama, J. Iida, M. Inoue et al., “Brain imaging in childhood- and adolescence-onset schizophrenia associated with obsessive-compulsive symptoms,” Acta Psychiatrica Scandinavica, vol. 102, no. 1, pp. 32–37, 2000. View at Publisher · View at Google Scholar · View at Scopus
  140. J. B. Levine, S. A. Gruber, A. A. Baird, and D. Yurgelun-Todd, “Obsessive-compulsive disorder among schizophrenic patients: an exploratory study using functional magnetic resonance imaging data,” Comprehensive Psychiatry, vol. 39, no. 5, pp. 308–311, 1998. View at Publisher · View at Google Scholar · View at Scopus
  141. M. Bleich-Cohen, T. Hendler, R. Weizman, S. Faragian, A. Weizman, and M. Poyurovsky, “Working memory dysfunction in schizophrenia patients with obsessive-compulsive symptoms: an fMRI study,” European Psychiatry, vol. 29, no. 3, pp. 160–166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  142. D. M. Coward, “General pharmacology of clozapine,” British Journal of Psychiatry, vol. 160, no. 17, pp. 5–11, 1992. View at Google Scholar · View at Scopus
  143. H. Y. Meltzer and M. Huang, “In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems,” Progress in Brain Research, vol. 172, pp. 177–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. H. Y. Meltzer, “Clozapine: balancing safety with superior antipsychotic efficacy,” Clinical Schizophrenia and Related Psychoses, vol. 6, no. 3, pp. 134–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  145. L. Duggan, M. Fenton, R. M. Dardennes, A. El-Dosoky, and S. Indran, “Olanzapine for schizophrenia,” Cochrane Database of Systematic Reviews, no. 1, 2003. View at Google Scholar · View at Scopus
  146. N. J. Van Der Wee, H. Stevens, J. A. Hardeman et al., “Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]β-CIT SPECT,” American Journal of Psychiatry, vol. 161, no. 12, pp. 2201–2206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Meyer-Lindenberg, “Imaging genetics of schizophrenia,” Dialogues in Clinical Neuroscience, vol. 12, no. 4, pp. 449–456, 2010. View at Google Scholar · View at Scopus
  148. J. Van Os, B. P. F. Rutten, and R. Poulton, “Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions,” Schizophrenia Bulletin, vol. 34, no. 6, pp. 1066–1082, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. P. D. Arnold, T. Sicard, E. Burroughs, M. A. Richter, and J. L. Kennedy, “Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder,” Archives of General Psychiatry, vol. 63, no. 7, pp. 769–776, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. D. E. Dickel, J. Veenstra-VanderWeele, N. J. Cox et al., “Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder,” Archives of General Psychiatry, vol. 63, no. 7, pp. 778–785, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. Y. Y. Shugart, Y. Wang, J. F. Samuels et al., “A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families,” American Journal of Medical Genetics B: Neuropsychiatric Genetics, vol. 150, no. 6, pp. 886–892, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. S. E. Stewart, J. A. Fagerness, J. Platko et al., “Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder,” American Journal of Medical Genetics B: Neuropsychiatric Genetics, vol. 144, no. 8, pp. 1027–1033, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. J. R. Wendland, P. R. Moya, K. R. Timpano et al., “A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder,” Archives of General Psychiatry, vol. 66, no. 4, pp. 408–416, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. L. Lykouras, B. Alevizos, P. Michalopoulou, and A. Rabavilas, “Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 3, pp. 333–346, 2003. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Schirmbeck and M. Zink, “Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review,” Current Neuropharmacology, vol. 10, no. 1, pp. 88–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  156. H. Y. Meltzer, “Role of serotonin in the action of atypical antipsychotic drugs,” Clinical Neuroscience, vol. 3, no. 2, pp. 64–75, 1995. View at Google Scholar · View at Scopus
  157. H. Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa, “Serotonin receptors: their key role in drugs to treat schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 7, pp. 1159–1172, 2003. View at Publisher · View at Google Scholar · View at Scopus
  158. X. López-Gil, F. Artigas, and A. Adell, “Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex,” Current Pharmaceutical Design, vol. 16, no. 5, pp. 502–515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. M. Zink, S. Englisch, and A. Schmitt, “Antipsychotic treatment modulates glutamate neurotransmission: From animal models to innovative treatment of schizophrenia,” European Archives of Psychiatry & Clinical Neuroscience. Submitted.
  160. J. S. Kwon, Y. H. Joo, H. J. Nam et al., “Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms,” Archives of General Psychiatry, vol. 66, no. 11, pp. 1233–1241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. R. W. Baker, K. N. R. Chengappa, J. W. Baird, S. Steingard, M. A. G. Christ, and N. R. Schooler, “Emergence of obsessive compulsive symptoms during treatment with clozapine,” Journal of Clinical Psychiatry, vol. 53, no. 12, pp. 439–442, 1992. View at Google Scholar · View at Scopus
  162. L. De Haan, D. H. Linszen, and R. Gorsira, “Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders,” Journal of Clinical Psychiatry, vol. 60, no. 6, pp. 364–365, 1999. View at Google Scholar · View at Scopus
  163. I. Reznik, I. Yavin, R. Stryjer et al., “Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study,” Pharmacopsychiatry, vol. 37, no. 2, pp. 52–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  164. R. Joober and P. Boksa, “Clozapine: a distinct, poorly understood and under-used molecule,” Journal of Psychiatry and Neuroscience, vol. 35, no. 3, pp. 147–149, 2010. View at Publisher · View at Google Scholar · View at Scopus
  165. J. M. Kane, “A user's guide to clozapine,” Acta Psychiatrica Scandinavica, vol. 123, no. 6, pp. 407–408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. X. Kang and G. M. Simpson, “Clozapine: more side effects but still the best antipsychotic,” Journal of Clinical Psychiatry, vol. 71, no. 8, pp. 982–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine,” Archives of General Psychiatry, vol. 45, no. 9, pp. 789–796, 1988. View at Google Scholar · View at Scopus
  168. J. P. McEvoy, J. A. Lieberman, T. S. Stroup et al., “Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment,” American Journal of Psychiatry, vol. 163, no. 4, pp. 600–610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  169. C. A. Lobos, K. Komossa, C. Rummel-Kluge et al., “Clozapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Gupta and D. G. Daniel, “Cautions in the clozapine-to-risperidone switch,” Annals of Clinical Psychiatry, vol. 7, no. 3, p. 149, 1995. View at Google Scholar · View at Scopus
  171. R. R. Conley, D. L. Kelly, C. M. Richardson, C. A. Tamminga, and W. T. Carpenter Jr., “The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind, crossover study,” Journal of Clinical Psychopharmacology, vol. 23, no. 6, pp. 668–671, 2003. View at Google Scholar · View at Scopus
  172. D. J. Still, P. G. Dorson, M. L. Crismon, and C. Pousson, “Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone,” Psychiatric Services, vol. 47, no. 12, pp. 1382–1384, 1996. View at Google Scholar · View at Scopus
  173. J. Tiihonen, J. Lönnqvist, K. Wahlbeck et al., “11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study),” The Lancet, vol. 374, no. 9690, pp. 620–627, 2009. View at Publisher · View at Google Scholar · View at Scopus
  174. A. B. Hill, “The environment and disease: association or causation?” Bulletin of the World Health Organization, vol. 58, no. 5, pp. 295–300, 2011. View at Google Scholar
  175. I. Berman, B. L. Sapers, H. H. J. Chang, M. F. Losonczy, J. Schmildler, and A. I. Green, “Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine,” Journal of Clinical Psychopharmacology, vol. 15, no. 3, pp. 206–210, 1995. View at Publisher · View at Google Scholar · View at Scopus
  176. G. Nolfe, W. Milano, G. Zontini et al., “Obsessive-compulsive symptoms in schizophrenia: their relationship with clinical features and pharmacological treatment,” Journal of Psychiatric Practice, vol. 16, no. 4, pp. 235–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  177. H. Hippius, “The history of clozapine,” Psychopharmacology, vol. 99, pp. S3–S5, 1989. View at Google Scholar · View at Scopus
  178. S.-K. Lin, S.-F. Su, and C.-H. Pan, “Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms,” Therapeutic Drug Monitoring, vol. 28, no. 3, pp. 303–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  179. M. Lim, D. Y. Park, J. S. Kwon, Y. H. Joo, and K. S. Hong, “Prevalence and clinical characteristics of obsessive-compulsive symptoms associated with atypical antipsychotics,” Journal of Clinical Psychopharmacology, vol. 27, no. 6, pp. 712–713, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. F. Schirmbeck, V. Nieratschker, J. Frank et al., “Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents,” Psychiatric Genetics, vol. 22, no. 5, pp. 245–252, 2012. View at Publisher · View at Google Scholar · View at Scopus
  181. A. Ertugrul, A. E. A. Yagcioglu, N. Eni, and K. M. Yazici, “Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients,” Psychiatry and Clinical Neurosciences, vol. 59, no. 2, pp. 219–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  182. H. Y. Meltzer and T. Sumiyoshi, “Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?” Behavioural Brain Research, vol. 195, no. 1, pp. 98–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. G. Remington, “Alterations of dopamine and serotonin transmission in schizophrenia,” Progress in Brain Research, vol. 172, pp. 117–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  184. D. A. Shapiro, S. Renock, E. Arrington et al., “Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology,” Neuropsychopharmacology, vol. 28, no. 8, pp. 1400–1411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  185. J. S. Chang, Y. M. Ahn, H. J. Park et al., “Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial,” Journal of Clinical Psychiatry, vol. 69, no. 5, pp. 720–731, 2008. View at Google Scholar · View at Scopus
  186. K. M. Connor, V. M. Payne, K. M. Gadde, W. Zhang, and J. R. T. Davidson, “The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients,” The Journal of clinical psychiatry, vol. 66, no. 1, pp. 49–51, 2005. View at Google Scholar · View at Scopus
  187. S. Englisch, C. Esslinger, D. Inta et al., “Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole,” Clinical Neuropharmacology, vol. 32, no. 4, pp. 227–229, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Englisch and M. Zink, “Combined antipsychotic treatment involving clozapine and aripiprazole,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 6, pp. 1386–1392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  189. M. Zink, U. Knopf, and A. Kuwilsky, “Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia,” Australian and New Zealand Journal of Psychiatry, vol. 41, no. 3, pp. 293–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  190. S.-W. Kim, I.-S. Shin, J.-M. Kim, S.-J. Yang, M. Y. Hwang, and J.-S. Yoon, “Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 349–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  191. L. Pani, J. M. Villagrán, V. P. Kontaxakis, and K. Alptekin, “Practical issues with amisulpride in the management of patients with schizophrenia,” Clinical Drug Investigation, vol. 28, no. 8, pp. 465–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  192. L. De Haan, N. Beuk, B. Hoogenboom, P. Dingemans, and D. Linszen, “Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders,” Journal of Clinical Psychiatry, vol. 63, no. 2, pp. 104–107, 2002. View at Google Scholar · View at Scopus
  193. F. L. Rocha and C. Hara, “Benefits of combining aripiprazole to clozapine: three case reports,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 6, pp. 1167–1169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  194. B. Peters and L. de Haan, “Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 33, no. 8, pp. 1576–1577, 2009. View at Publisher · View at Google Scholar · View at Scopus
  195. L. Van Nimwegen, L. De Haan, N. Van Beveren, W. Laan, W. Van Den Brink, and D. Linszen, “Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis,” Journal of Clinical Psychopharmacology, vol. 28, no. 2, pp. 214–218, 2008. View at Publisher · View at Google Scholar · View at Scopus
  196. M. R. A. Muscatello, A. Bruno, G. Pandolfo et al., “Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study,” Journal of Clinical Psychopharmacology, vol. 31, no. 2, pp. 174–179, 2011. View at Publisher · View at Google Scholar · View at Scopus
  197. S. Steingard, K. N. R. Chengappa, R. W. Baker et al., “Clozapine, obsessive symptoms, and serotonergic mechanisms,” American Journal of Psychiatry, vol. 150, no. 9, p. 1435, 1993. View at Google Scholar · View at Scopus
  198. H. Y. Meltzer, “An overview of the mechanism of action of clozapine,” Journal of Clinical Psychiatry, vol. 55, no. 9, pp. 47–52, 1994. View at Google Scholar · View at Scopus
  199. C. U. Correll, “Antipsychotic polypharmacy, Part 2: why use 2 antipsychotics when 1 is not good enough?” Journal of Clinical Psychiatry, vol. 69, no. 5, pp. 860–861, 2008. View at Google Scholar · View at Scopus
  200. B. Scatton, Y. Claustre, A. Cudennec et al., “Amisulpride: from animal pharmacology to therapeutic action,” International Clinical Psychopharmacology, vol. 12, no. 2, pp. S29–S36, 1997. View at Google Scholar · View at Scopus
  201. S. Ryu, S. Oh, E.-Y. Cho et al., “Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms,” American Journal of Medical Genetics B: Neuropsychiatric Genetics, vol. 156, no. 8, pp. 949–959, 2011. View at Publisher · View at Google Scholar · View at Scopus
  202. J. Cai, W. Zhang, Z. Yi et al., “Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms,” Psychopharmacology, vol. 230, no. 1, pp. 49–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  203. H. M. Hashim, N. Fawzy, M. M. Fawzi, and R. A. Karam, “Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients,” Journal of Psychiatric Research, vol. 46, no. 6, pp. 762–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  204. F. Schirmbeck and M. Zink, “Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors,” Frontiers in Pharmacology, vol. 4, Article ID Article 99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  205. M. Doyle, A. N. Chorcorain, E. Griffith, T. Trimble, and E. O'Callaghan, “Obsessive compulsive symptoms in patients with Schizophrenia on Clozapine and with Obsessive Compulsive disorder: a comparison study,” Comprehensive Psychiatry, vol. 55, no. 1, pp. 130–136, 2013. View at Publisher · View at Google Scholar
  206. J. Van Os, G. Kenis, and B. P. F. Rutten, “The environment and schizophrenia,” Nature, vol. 468, no. 7321, pp. 203–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  207. R. Keers and R. Uher, “Gene-environment interaction in major depression and antidepressant treatment response,” Current Psychiatry Reports, vol. 14, no. 2, pp. 129–137, 2012. View at Publisher · View at Google Scholar · View at Scopus
  208. A. M. Gregory, J. Y. F. Lau, and T. C. Eley, “Finding gene-environment interactions for generalised anxiety disorder,” European Archives of Psychiatry and Clinical Neuroscience, vol. 258, no. 2, pp. 69–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  209. N. R. Nugent, A. R. Tyrka, L. L. Carpenter, and L. H. Price, “Gene-environment interactions: early life stress and risk for depressive and anxiety disorders,” Psychopharmacology, vol. 214, no. 1, pp. 175–196, 2011. View at Publisher · View at Google Scholar · View at Scopus
  210. G. Eryilmaz, G. H. Sayar, E. Ozten, I. Gögcegöz, and O. Karamustafalioglu, “Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia,” Annals of General Psychiatry, vol. 12, p. 40, 2013. View at Publisher · View at Google Scholar
  211. K.-C. Yang, T.-P. Su, and Y.-H. Chou, “Effectiveness of aripiprazole in treating obsessive compulsive symptoms,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 2, pp. 585–586, 2008. View at Publisher · View at Google Scholar · View at Scopus
  212. M. Poyurovsky, V. Isakov, S. Hromnikov et al., “Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study,” International Clinical Psychopharmacology, vol. 14, no. 2, pp. 95–100, 1999. View at Google Scholar · View at Scopus
  213. I. Reznik and P. Sirota, “Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics,” Journal of Clinical Psychopharmacology, vol. 20, no. 4, pp. 410–416, 2000. View at Publisher · View at Google Scholar · View at Scopus
  214. F. Canan, U. Aydinoglu, and G. Sinani, “Valproic acid augmentation in clozapine-associated hand-washing compulsion,” Psychiatry and Clinical Neurosciences, vol. 66, no. 5, pp. 463–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  215. M. Zink, S. Englisch, U. Knopf, A. Kuwilsky, and H. Dressing, “Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms,” Pharmacopsychiatry, vol. 40, no. 5, pp. 202–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  216. C. I. Rodriguez, C. Corcoran, and H. B. Simpson, “Diagnosis and treatment of a patient with both psychotic and obsessive-compulsive symptoms,” American Journal of Psychiatry, vol. 167, no. 7, pp. 754–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  217. A. Tundo, L. Salvati, D. Di Spigno et al., “Cognitive-behavioral therapy for obsessive-compulsive disorder as a comorbidity with schizophrenia or schizoaffective disorder,” Psychotherapy and Psychosomatics, vol. 81, no. 1, pp. 58–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  218. P. M. G. Emmelkamp and P. van Oppen, Zwangsstörungen, Hogrefe, Göttingen, Germany, 2000.
  219. U. Foerstner, A. M. Kuelz, and U. Voderholzer, Störungsspezifische Behandlung Der Zwangsstörungen: Ein Therapiemanual, Kohlhammer, Stuttgart, Germany, 2011.
  220. A. Lakatos and H. Reinecker, Kognitive Verhaltenstherapie Bei Zwangsstörungen: Ein Therapiemanual, Hogrefe, Göttingen, Germany, 2007.
  221. C. Oelkers, M. Hautzinger, and M. Bleibel, Zwangsst+Ârungen: Ein Kognitiv-Verhaltenstherapeutisches Behandlungsmanual, Beltz Psychologie Verlags Union, Weinheim, Germany, 2007.